Bortezomib is an anti-tumor agent, which inhibits 26S proteasome degrading ubiquitinated proteins. While apoptotic transcription-associated activation in response to bortezomib has been suggested, mechanisms related to its influence on post-transcriptional gene silencing mediated regulation by non-coding RNAs remain not fully elucidated. In the present study, we examined changes in global gene and miRNA expression and analyzed the identified miRNA–mRNA interactions after bortezomib exposure in human neuroblastoma cells to define pathways affected by this agent in this type of cells. Cell viability assays were performed to assess cytotoxicity of bortezomib. Global gene and miRNA expression profiles of neuroblastoma cells after 24-h in...
The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-ref...
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination ...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Multiple myeloma (MM) is a malignant cancer with an increasing in incidence that can be alleviated t...
and the role of miR-3151 was first evaluated in SKM-1 cells.SKM-1 cells were treated with different...
Bortezomib/PS-341/Velcade, a proteasome inhibitor, is widely used to treat multiple myeloma. While s...
Inhibition of the proteasome is considered as a promising strategy to sensitize cancer cells to apop...
<p>(A) cMyc protein levels after bortezomib treatment (4 nM) at the indicated time points in CTCL ce...
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple m...
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple m...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of progressio...
© 2016 Elsevier B.V. Bortezomib is a proteasome inhibitor with a remarkable antitumor activity, used...
Activated B-cell type lymphoma (ABC), a subgroup of diffuse large B-cell lymphoma (DLBCL), has a wor...
The boronic acid dipeptide bortezomib, able to induce tumor cell death by degradation of key protein...
The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-ref...
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination ...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Multiple myeloma (MM) is a malignant cancer with an increasing in incidence that can be alleviated t...
and the role of miR-3151 was first evaluated in SKM-1 cells.SKM-1 cells were treated with different...
Bortezomib/PS-341/Velcade, a proteasome inhibitor, is widely used to treat multiple myeloma. While s...
Inhibition of the proteasome is considered as a promising strategy to sensitize cancer cells to apop...
<p>(A) cMyc protein levels after bortezomib treatment (4 nM) at the indicated time points in CTCL ce...
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple m...
MicroRNAs (miRNAs) with tumor-suppressor potential might have therapeutic applications in multiple m...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...
Myelodysplastic syndromes (MDS) are clonal marrow stem-cell disorders with a high risk of progressio...
© 2016 Elsevier B.V. Bortezomib is a proteasome inhibitor with a remarkable antitumor activity, used...
Activated B-cell type lymphoma (ABC), a subgroup of diffuse large B-cell lymphoma (DLBCL), has a wor...
The boronic acid dipeptide bortezomib, able to induce tumor cell death by degradation of key protein...
The proteasome inhibitor bortezomib (Velcade) was recently approved for the treatment of therapy-ref...
The proteasome inhibitor bortezomib has shown impressive clinical activity alone and in combination ...
Bortezomib is a proteasome inhibitor. It targets the ubiquitin-proteasome pathway with subsequent in...